About us
Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases.
The company’s lead program is a first-in-class CD31×GPVI bispecific antibody being developed for the treatment of thromboinflammatory diseases.
This novel approach provides both antithrombotic and anti-inflammatory efficacy while minimizing bleeding risk, thereby addressing major critical medical unmet needs in the field.
Our company is financed by leading European investors and led by an experienced management team.
Our Team
Management
Scientific team
Science
CD31: An inhibitory immune
checkpoint receptor
- CD31 (PECAM-1) belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and is broadly expressed by endothelial cells, platelets, and immune cells.
- Tyrosine phosphorylation of the CD31 ITIMs promotes the recruitment of the tyrosine phosphatases SHP-1 and SHP-2, which inhibit signaling pathways downstream of immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, thereby suppressing pathogenic cell activation.
Bispecific antibodies platform
- Dual-targeting bispecific antibodies combining anti-CD31 agonism with ITAM receptor targeting.
- Fc-silent format with rapid onset of action and IgG-like pharmacokinetics.
- Cell-specific ITIM-mediated immunomodulation that restores immune homeostasis while minimizing immunosuppression.
Lead program
CD31xGPVI BISPECIFIC ANTIBODY
GPVI AS A THERAPEUTIC TARGET
- GPVI is a novel, hemostasis-sparing target with dual antithrombotic and anti-inflammatory activity.
- GPVI links thrombosis and inflammation through platelet-leukocyte and platelet-endothelial crosstalk.
- Inherited GPVI deficiency is associated with minimal bleeding, unlike anticoagulant therapies or P2Y₁₂ inhibitors.
THERAPEUTIC PROFILE
CD31xGPVI bispecific antibody:
- Inhibits collagen-driven platelet activation and aggregation.
- Blocks thrombus formation under arterial flow in microfluidic assays using collagen or human atherosclerotic plaque material.
- Prevents platelet-leukocyte aggregates formation, thereby reducing NETosis.
- Preserves platelet responses to ADP, thrombin, and thromboxane A₂, maintaining alternative hemostatic pathways.
- Offers broad therapeutic potential across acute (ST-segment elevation myocardial infarction (STEMI), stroke) and chronic (peripheral artery disease, abdominal aortic aneurysm) thromboinflammatory cardiovascular diseases.
Antibody-mediated CD31 agonism inhibits activatory signal induced by ITAM receptors
Antibody-mediated CD31 agonism inhibits
activatory signal induced by ITAM receptors
Board Of Directors
Members
Observers
Scientific founders
Investors
Tridek-One Therapeutics has raised a total of €11 million to-date in equity and secured €1.9 million in Deeptech financing from Bpifrance.
News
TRIDEK-ONE SECURES €1.9 MILLION IN DEEP TECH FINANCING FROM BPIFRANCE
Financial support will enable company to pursue the identification and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance.
TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP FIRST-IN-CLASS IMMUNE CHECKPOINT AGONISTS
Paris, France, September 15, 2022 – Tridek-One SAS, a biotech start-up and leader in the research and development of CD31 agonists to restore the immune balance, closed a € 16 million new round of financing led by Pureos Bioventures with participation of new investors bpifrance and Bioqube Ventures and historical investors
TRIDEK-ONE raises € 3 million from Advent France Biotechnology and Advent Life Sciences
Tridek One, Paris, June 4, 2019 – Tridek-One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of € 3 million with leading investors Advent France Biotechnology and Advent Life Sciences.